Peter Rasmussen

Comptroller/Controller/Auditor at ASCENDIS PHARMA A/S

Net worth: 53 540 $ as of 2024-04-29

55 year

Health Technology

Consumer Services

Peter Rasmussen active positions

Companies	Position	Start	End
ASCENDIS PHARMA A/S	Comptroller/Controller/Auditor	2014-02-28	-
ASCENDIS PHARMA A/S	Director of Finance/CFO	2016-01-31	2016-07-31

Companies	Position	Start	End
AdvanDx, Inc. AdvanDx, Inc. Medical SpecialtiesHealth Technology AdvanDx, Inc. provides advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. Its products include QuickFISH BC Tests, PNA FISH Tests, ASR PNA Probes, starter system, accessories and package inserts. The firm offers diagnostic solutions that include antimicrobial stewardship, blood culture contamination, staphylococcal bacteremia, enterococcal bacteremia, gram-negative bacteremia and candidemia. The company was founded by Henrik Stender and Thais T. Johansen in 2002 and is headquartered in Woburn, MA.	Director of Finance/CFO	2008-05-31	2012-07-31
VELOXIS PHARMACEUTICALS A/S	Director of Finance/CFO	2006-12-31	2007-12-31

Copenhagen Business School

Graduate Degree

International

Denmark	4
United States	2

Operational

Director of Finance/CFO	3
Graduate Degree	1
Comptroller/Controller/Auditor	1

Sectoral

Health Technology	4
Consumer Services	2

Positions held

Active

Inactive

Listed companies

Private companies

Listed companies	1
ASCENDIS PHARMA A/S	Health Technology

Private companies	2
AdvanDx, Inc. AdvanDx, Inc. Medical SpecialtiesHealth Technology AdvanDx, Inc. provides advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. Its products include QuickFISH BC Tests, PNA FISH Tests, ASR PNA Probes, starter system, accessories and package inserts. The firm offers diagnostic solutions that include antimicrobial stewardship, blood culture contamination, staphylococcal bacteremia, enterococcal bacteremia, gram-negative bacteremia and candidemia. The company was founded by Henrik Stender and Thais T. Johansen in 2002 and is headquartered in Woburn, MA.	Health Technology
Veloxis Pharmaceuticals A/S Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark.	Health Technology

Private companies

Health Technology